Nielsen BioSciences

Executive Summary

Nielsen BioSciences is a privately-held biopharmaceutical company based in San Diego, California, specializing in biological products that evaluate and modulate cell-mediated immune responses. The company has established a commercial footprint with two FDA-approved delayed-type hypersensitivity (DTH) skin test antigens: CANDIN and SPHERUSOL. These products are used to assess immune competence and detect exposure to specific fungal pathogens, generating recurring revenue from the clinical diagnostics market. This commercial foundation provides financial stability and validates the company's expertise in cell-mediated immunity. Beyond diagnostics, Nielsen is advancing an immunotherapy program leveraging CANDIN as a therapeutic antigen. The program is entering Phase 3 trials for the treatment of HPV-related conditions, including anogenital warts and potentially cervical dysplasia. If successful, CANDIN could address a significant unmet need in HPV immunotherapy, offering a non-surgical, immune-based approach. The upcoming Phase 3 data readouts and potential regulatory milestones represent key value inflection points. With a disciplined focus and commercial assets already in market, Nielsen BioSciences presents a balanced risk-reward profile for investors seeking exposure to both established diagnostic revenue and a late-stage immunotherapy catalyst.

Upcoming Catalysts (preview)

• Q3 2026Phase 3 trial initiation for CANDIN in HPV-related conditions70% success
• Q4 2026Interim or final Phase 3 data readout for CANDIN60% success
• TBDPotential FDA label expansion or new indication for SPHERUSOL50% success